Quantcast
Home > Quotes > PTI

Proteostasis Therapeutics, Inc. Common Stock (PTI) Quote & Summary Data

PTI 
$4.74
*  
0.01
0.21%
Get PTI Alerts
*Delayed - data as of Dec. 10, 2018 10:40 ET  -  Find a broker to begin trading PTI now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    PTI Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 4.71 / $ 4.74
Today's High / Low
$ 4.9364 / $ 4.6975
Share Volume
32,295
50 Day Avg. Daily Volume
3,405,043
Previous Close
$ 4.75
52 Week High / Low
$ 10.38 / $ 1.71
Market Cap
240,831,920
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %

Intraday Chart

Shares Traded

Share Volume:
32,295
50 Day Avg. Daily Volume:
3,405,043

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.76

Trading Range

The current last sale of $4.74 is 177.19% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 4.9364 $ 10.38
 Low: $ 4.6975 $ 1.71

Company Description (as filed with the SEC)

We are an innovative, clinical stage biopharmaceutical company committed to the discovery and development of novel therapeutics to treat cystic fibrosis, or CF, and other diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance. The Company focuses on identifying therapies that restore protein function. CF is a disease caused by defects in the function or abundance of cystic fibrosis transmembrane conductance regulator, or CFTR. Our CF focused pipeline consists of novel CFTR modulators including correctors, potentiators and amplifiers. Upon discovery of amplifiers, a novel class of CFTR modulators, we have exploited its novel mechanism of action as a drug screening tool and have subsequently identified correctors and potentiators to be developed as part of combination therapies.  ... More ...  


Risk Grade

Where does PTI fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 4.78
Open Date:
Dec. 10, 2018
Close Price:
N/A
Close Date:
N/A

Consensus Recommendation

Analyst Info